Innate Pharma Adr (IPHA)

Nov 01, 2025

Innate Pharma FY2025 EPS Forecast Increased by HC Wainwright - MarketBeat

Nov 01, 2025

Nov 01, 2025

Innate Pharma (NASDAQ:IPHA) Stock Price Down 3.9%Time to Sell? - MarketBeat

Nov 01, 2025

Oct 23, 2025

Lucid Capital Markets initiates coverage on Innate Pharma stock with Buy rating - Investing.com India

Oct 23, 2025

Oct 09, 2025

Goldman Sachs Sticks to Their Hold Rating for Innate Pharma SA (IPHYF) - Barchart.com

Oct 09, 2025

Sep 22, 2025

Leerink Partnrs Forecasts Innate Pharma Q3 Earnings - Defense World

Sep 22, 2025

Sep 22, 2025

Innate Pharma FY2025 EPS Estimate Increased by HC Wainwright - MarketBeat

Sep 22, 2025

Sep 20, 2025

Innate Pharma (NASDAQ:IPHA) Downgraded by HC Wainwright to “Neutral” - Defense World

Sep 20, 2025

Sep 19, 2025

Innate Pharma (NASDAQ:IPHA) Given “Market Perform” Rating at Leerink Partners - Defense World

Sep 19, 2025

Sep 18, 2025

Leerink Partners downgrades Innate Pharma stock on shift to ADC strategy - Investing.com

Sep 18, 2025

Sep 18, 2025

Innate Pharma SA Reports First Half 2025 Financial Results - TipRanks

Sep 18, 2025

Sep 17, 2025

Innate Pharma H1 2025 slides: strategic refocus on key assets extends cash runway By Investing.com - Investing.com South Africa

Sep 17, 2025

Sep 17, 2025

Earnings call transcript: Innate Pharma’s Q2 2025 focus on strategic assets - Investing.com

Sep 17, 2025

Sep 17, 2025

Innate Pharma H1 2025 slides: strategic refocus on key assets extends cash runway - Investing.com

Sep 17, 2025

Sep 17, 2025

Innate Pharma Reports First Half 2025 Business Update and Financial Results - Placera.se

Sep 17, 2025

Sep 13, 2025

Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) Short Interest Down 25.8% in August - MarketBeat

Sep 13, 2025

Sep 04, 2025

Innate Pharma (NASDAQ:IPHA) Trading 1.7% HigherWhat's Next? - MarketBeat

Sep 04, 2025

Aug 30, 2025

Innate Pharma (NASDAQ:IPHA) Trading 1.7% Higher – Here’s What Happened - Defense World

Aug 30, 2025

Jul 31, 2025

Arm Holdings PLC Releases Q2 2025 Financial Report Amid Market Challenges - The Globe and Mail

Jul 31, 2025

Jul 28, 2025

How strong is Innate Pharma S.A. Depositary Receipt company’s balance sheetSuperior risk-adjusted returns - Jammu Links News

Jul 28, 2025

Jul 28, 2025

Innate Pharma stock initiated with Buy rating at BTIG on cancer therapy potential - Investing.com

Jul 28, 2025

Jul 24, 2025

Non-Hodgkin’s Lymphoma Market Forecast to Surge with Growing Adoption of Targeted and Cell-Based Therapies | DelveInsight - GlobeNewswire Inc.

Jul 24, 2025

Jul 17, 2025

Innate Pharma (NASDAQ:IPHA) Trading 1.7% Higher – What’s Next? - Defense World

Jul 17, 2025

Jun 25, 2025

Exchange Traded Concepts LLC Has $112,000 Stock Position in Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) - Defense World

Jun 25, 2025

May 28, 2025

Why Kingsoft Cloud Holdings Stock Plummeted by Nearly 8% Today - The Globe and Mail

May 28, 2025

May 26, 2025

Should You Buy, Hold, or Sell PDD Holdings Stock Before Q1 Earnings? - The Globe and Mail

May 26, 2025

May 13, 2025

Earnings call transcript: Innate Pharma Q1 2025 earnings reveal strategic focus By Investing.com - Investing.com South Africa

May 13, 2025

May 13, 2025

Earnings call transcript: Innate Pharma Q1 2025 earnings reveal strategic focus - Investing.com India

May 13, 2025

May 13, 2025

Innate Pharma Q1 2025 slides: pipeline advances and Sanofi partnership strengthen outlook - Investing.com

May 13, 2025

May 13, 2025

Innate Pharma Q1 2025 slides: pipeline advances and Sanofi partnership strengthen outlook By Investing.com - Investing.com South Africa

May 13, 2025

Apr 30, 2025

Innate Pharma reports promising preclinical results for cancer drug IPH4502 By Investing.com - Investing.com India

Apr 30, 2025

Apr 29, 2025

Innate Pharma stock surges on promising preclinical data By Investing.com - Investing.com South Africa

Apr 29, 2025

Apr 29, 2025

Innate Pharma reports promising preclinical results for cancer drug IPH4502 - Investing.com

Apr 29, 2025

Apr 24, 2025

H.C. Wainwright maintains $11 target on Innate Pharma stock - Investing.com

Apr 24, 2025

Nov 14, 2024

Earnings call: Innate Pharma Q3 2024 results highlight oncology pipeline - Investing.com

Nov 14, 2024

Nov 07, 2024

AZN Stock Price and Chart — NASDAQ:AZN - TradingView

Nov 07, 2024

Jun 10, 2024

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday - TradingView

Jun 10, 2024

Mar 31, 2024

symbol__ Stock Quote Price and Forecast - CNN

Mar 31, 2024

Jan 04, 2024

Innate Pharma (IPHA) Gains as FDA Lifts Hold on Lymphoma Study - Nasdaq

Jan 04, 2024

Mar 13, 2023

What is the current Price Target and Forecast for Innate Pharma (IPHA) - Zacks Investment Research

Mar 13, 2023

Dec 19, 2022

Innate, Sanofi ink licensing deal for NK cells - MarketWatch

Dec 19, 2022

Aug 01, 2022

Innate Pharma: AstraZeneca To Discontinue INTERLINK-1 Monalizumab Combination Trial - Nasdaq

Aug 01, 2022

Apr 29, 2022

Innate Pharma Gets $50 Million From AstraZeneca as Monalizumab Phase 3 Lung Cancer Trial Begins - Equities.com

Apr 29, 2022

Dec 16, 2021

ICE Announces Annual Reconstitution Changes in the ICE Biotechnology Index - FinancialContent

Dec 16, 2021

Nov 01, 2019

Innate Pharma (IPHA) Stock Price, News & Analysis - MarketBeat

Nov 01, 2019

Oct 25, 2019

Innate Pharma Share Price ADR EACH REPR 1 ORD SPON - Hargreaves Lansdown

Oct 25, 2019

Apr 24, 2015

AstraZeneca and Innate Pharma announce global co-development and commercialisation collaboration for IPH2201 in immuno-oncology - AstraZeneca

Apr 24, 2015